TY - JOUR
T1 - Genome Editing Provides New Insights into Receptor-Controlled Signalling Pathways
AU - Milligan, Graeme
AU - Inoue, Asuka
N1 - Funding Information:
Work described in this article was supported by the UK Biotechnology and Biological Sciences Research Council (grants BB/L027887/1 and BB/K019864/1) to G.M.; and by Japan Science and Technology Agency (JST; JPMJPR1331), Japan Agency for Medical Research and Development (AMED; JP17gm5910013), and Japan Society for the Promotion of Science (JSPS) KAKENHI (17K08264) funding to A.I. We thank Kouki Kawakami (Tohoku University, Japan) and Yu Hisano (Harvard Medical School, USA) for advice on designing of sgRNA sequences.
Funding Information:
Work described in this article was supported by the UK Biotechnology and Biological Sciences Research Council (grants BB/L027887/1 and BB/K019864/1 ) to G.M.; and by Japan Science and Technology Agency (JST; JPMJPR1331 ), Japan Agency for Medical Research and Development (AMED; JP17gm5910013 ), and Japan Society for the Promotion of Science (JSPS) KAKENHI ( 17K08264 ) funding to A.I. We thank Kouki Kawakami (Tohoku University, Japan) and Yu Hisano (Harvard Medical School, USA) for advice on designing of sgRNA sequences.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/5
Y1 - 2018/5
N2 - Rapid developments in genome editing, based largely on CRISPR/Cas9 technologies, are offering unprecedented opportunities to eliminate the expression of single or multiple gene products in intact organisms and in model cell systems. Elimination of individual G protein-coupled receptors (GPCRs), both single and multiple G protein subunits, and arrestin adaptor proteins is providing new and sometimes unanticipated insights into molecular details of the regulation of cell signalling pathways and the behaviour of receptor ligands. Genome editing is certain to become a central component of therapeutic target validation, and will provide pharmacologists with new understanding of the complexities of action of novel and previously studied ligands, as well as of the transmission of signals from individual cell-surface receptors to intracellular signalling cascades.
AB - Rapid developments in genome editing, based largely on CRISPR/Cas9 technologies, are offering unprecedented opportunities to eliminate the expression of single or multiple gene products in intact organisms and in model cell systems. Elimination of individual G protein-coupled receptors (GPCRs), both single and multiple G protein subunits, and arrestin adaptor proteins is providing new and sometimes unanticipated insights into molecular details of the regulation of cell signalling pathways and the behaviour of receptor ligands. Genome editing is certain to become a central component of therapeutic target validation, and will provide pharmacologists with new understanding of the complexities of action of novel and previously studied ligands, as well as of the transmission of signals from individual cell-surface receptors to intracellular signalling cascades.
KW - CRISPR/Cas9
KW - G protein
KW - G protein-coupled receptor
KW - arrestin
KW - genome editing
UR - http://www.scopus.com/inward/record.url?scp=85043469649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043469649&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2018.02.005
DO - 10.1016/j.tips.2018.02.005
M3 - Review article
C2 - 29548548
AN - SCOPUS:85043469649
VL - 39
SP - 481
EP - 493
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
SN - 0165-6147
IS - 5
ER -